Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Equity Bottom-Up

<div><ul><li>Meet the CEO. Rick Pierce moved into biotechnology after a 15-year Wall Street career advising biotech and pharmaceutical clients at Lehman Brothers.</li><li>Decoy is the fifth public company he has founded or co-founded, following a prior venture that was acquired by Pfizer after earning European drug approval.</li><li>He launched Decoy five years ago with MIT Professor Brad Pentelute to accelerate peptide-conjugate drug development.</li></ul></div>

Meet the CEO. Rick Pierce moved into biotechnology after a 15-year Wall Street career advising biotech and pharmaceutical clients at Lehman Brothers.Decoy is the fifth public company he has founded or co-founded, following a prior venture that was acquired by Pfizer after earning European drug approval.He launched Decoy five years ago with MIT Professor Brad Pentelute to accelerate peptide-conjugate drug development.

Decoy Therapeutics' (DCOY) Groundbreaking Approach to Drug Development in the AI/ML Era

United States

Decoy Therapeutics Inc. operates as a preclinical-stage biotechnology company. The Company specializes in drug development and manufacturing peptide conjugate therapeutics that focuses on respiratory viruses and GI cancers. Decoy Therapeutics serves customers in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00